Skip to main
KTTA

KTTA Stock Forecast & Price Target

KTTA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pasithea Therapeutics is poised to make a significant impact in the treatment of NF1 and other diseases, and their strong pipeline and potential for growth make them a promising investment opportunity.

Bears say

Pasithea Therapeutics is a biotechnology company focused on developing treatments for central nervous system disorders and other diseases. While their current pipelines show potential promise, the company faces several challenges, including regulatory hurdles, a limited market for their treatments, and competition from traditional MEK inhibitors. Additionally, their valuation is based on assumptions and may be subject to change as their clinical trials progress. Ultimately, the success of Pasithea Therapeutics will depend on their ability to effectively navigate these challenges and bring their treatments to market.

KTTA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pasithea Therapeutics Corp (KTTA) Forecast

Analysts have given KTTA a Strong Buy based on their latest research and market trends.

According to 1 analysts, KTTA has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pasithea Therapeutics Corp (KTTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.